Skip Nav Destination
Issues
1 June 2015
-
Cover Image
Cover Image
Some lupus autoantibodies penetrate into live cells, and the potential to use these cell-penetrating antibodies against cancer is an emerging concept. An optimized lupus anti-DNA antibody construct, 3E10 di-scFv, has now been shown to localize into cell nuclei and to selectively cause accumulation of DNA damage in and kill cancer cells with certain defects in DNA repair and therefore has potential in targeted cancer therapy. In this image the fluorescent signal demonstrates nuclear localization by the optimized lupus antibody construct in DLD1 colon cancer cells that were immunostained after treatment with 3E10 di-scFv. For details, see article by Noble and colleagues on page 2285. - PDF Icon PDF LinkTable of Contents
ISSN 0008-5472
EISSN 1538-7445
Cancer Research
Table of Contents
Breaking Advances
Reviews
Priority Reports
Author Choice
Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM
Nuala McCabe; Conor Hanna; Steven M. Walker; David Gonda; Jie Li; Katarina Wikstrom; Kienan I. Savage; Karl T. Butterworth; Clark Chen; D. Paul Harkin; Kevin M. Prise; Richard D. Kennedy
Microenvironment and Immunology
Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell–Engaging Antibody and CD8 T Cells
Shruthi Prasad; Simone Gaedicke; Marcia Machein; Gerhard Mittler; Friederike Braun; Michael Hettich; Elke Firat; Kerstin Klingner; Julia Schüler; Dagmar Wider; Ralph M. Wäsch; Christel Herold-Mende; Ursula Elsässer-Beile; Gabriele Niedermann
JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
Kathrin Schönberg; Janna Rudolph; Maria Vonnahme; Sowmya Parampalli Yajnanarayana; Isabelle Cornez; Maryam Hejazi; Angela R. Manser; Markus Uhrberg; Walter Verbeek; Steffen Koschmieder; Tim H. Brümmendorf; Peter Brossart; Annkristin Heine; Dominik Wolf
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
Hyun-Bae Jie; Patrick J. Schuler; Steve C. Lee; Raghvendra M. Srivastava; Athanassios Argiris; Soldano Ferrone; Theresa L. Whiteside; Robert L. Ferris
Molecular and Cellular Pathobiology
Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications
Angelo Gámez-Pozo; Julia Berges-Soria; Jorge M. Arevalillo; Paolo Nanni; Rocío López-Vacas; Hilario Navarro; Jonas Grossmann; Carlos A. Castaneda; Paloma Main; Mariana Díaz-Almirón; Enrique Espinosa; Eva Ciruelos; Juan Ángel Fresno Vara
Hepcidin Regulation in Prostate and Its Disruption in Prostate Cancer
Lia Tesfay; Kathryn A. Clausen; Jin Woo Kim; Poornima Hegde; Xiaohong Wang; Lance D. Miller; Zhiyong Deng; Nicole Blanchette; Tara Arvedson; Cindy K. Miranti; Jodie L. Babitt; Herbert Y. Lin; Donna M. Peehl; Frank M. Torti; Suzy V. Torti
Therapeutics, Targets, and Chemical Biology
Ormeloxifene Suppresses Desmoplasia and Enhances Sensitivity of Gemcitabine in Pancreatic Cancer
Sheema Khan; Mara C. Ebeling; Neeraj Chauhan; Paul A. Thompson; Rishi K. Gara; Aditya Ganju; Murali M. Yallapu; Stephen W. Behrman; Haotian Zhao; Nadeem Zafar; Man Mohan Singh; Meena Jaggi; Subhash C. Chauhan
Tumor and Stem Cell Biology
Author Choice
miR-25 Modulates Invasiveness and Dissemination of Human Prostate Cancer Cells via Regulation of αv- and α6-Integrin Expression
E. Zoni; G. van der Horst; A.F. van de Merbel; L. Chen; J.K. Rane; R.C.M. Pelger; A.T. Collins; T. Visakorpi; B.E. Snaar-Jagalska; N.J. Maitland; G. van der Pluijm
Author Choice
Vimentin–ERK Signaling Uncouples Slug Gene Regulatory Function
Reetta Virtakoivu; Anja Mai; Elina Mattila; Nicola De Franceschi; Susumu Y. Imanishi; Garry Corthals; Riina Kaukonen; Markku Saari; Fang Cheng; Elin Torvaldson; Veli-Matti Kosma; Arto Mannermaa; Ghaffar Muharram; Christine Gilles; John Eriksson; Ylermi Soini; James B. Lorens; Johanna Ivaska
SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias
Caterina Vitali; Claudia Bassani; Claudia Chiodoni; Elisa Fellini; Carla Guarnotta; Silvia Miotti; Sabina Sangaletti; Fabio Fuligni; Loris De Cecco; Pier P. Piccaluga; Mario P. Colombo; Claudio Tripodo
Letter to the Editor
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds